Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 463 across all filing types
Latest filing 2021-02-01 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2021-02-01 English
Financial Results Updates
Regulatory Filings
2021-02-01 English
Outcome of Board Meeting
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges reporting the outcome of a Board Meeting held on February 1, 2021. It specifically states that the Board considered, approved, and took on record the Unaudited Financial Results for the quarter ended December 31, 2020. It also mentions that a Limited Review Report by the Statutory Auditors is attached. The document is short (1619 characters) and primarily serves as an announcement of the financial results and the board meeting outcome rather than containing the full financial statements or detailed analysis. According to the rules, such announcements of financial results and board meeting outcomes fall under Regulatory Filings (RNS) because it is not the full interim report itself but an announcement of the results and meeting outcome. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-02-01 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of a scheduled Board Meeting to consider and approve unaudited financial results for the quarter ended December 30, 2020. It is an intimation to stock exchanges and public about the upcoming board meeting, not the financial results report itself. The document is short (1884 characters) and serves as a meeting notice rather than containing substantive financial data or analysis. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a board meeting and financial results approval, not the actual report or earnings release.
2021-01-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2020. It is issued by the Registrar and Share Transfer Agent confirming dematerialization and securities handling compliance. The document is a regulatory compliance certificate, not a financial report or announcement of financial results. It is short (2689 characters) and serves as a certification letter to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a full report or announcement of a report.
2021-01-18 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Lasa Supergenerics received WHO certification for its manufacturing unit. It is titled 'Media Release' and contains no financial data, regulatory filings, or detailed report content. The document is short (3472 characters) and serves as an announcement rather than a detailed report or filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a Regulatory Filings (RNS) type since it is a general regulatory announcement and does not fit other specific categories.
2021-01-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.